FDA issues warning letter to ImmunityBio over misleading promotion of NAI
The FDA has issued a warning letter to ImmunityBio regarding misleading promotional content for its drug nogapendekin alfa inbakicept-pmln (NAI; Anktiva). The agency cited a direct-to-consumer advertisement and a podcast for overstating efficacy, omitting risk information, and suggesting unapproved uses, specifically implying it could cure or prevent cancer broadly. ImmunityBio has since removed the podcast, stated the TV ad was not aired, and implemented corrective actions including enhanced promotional review processes and executive training to address the FDA's concerns.
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
ImmunityBio (IBRX) has responded to a March 2026 FDA Warning Letter regarding promotional materials for its drug ANKTIVA. The company removed the cited podcast, confirmed a related TV ad was never aired, and implemented comprehensive compliance measures including executive training and external regulatory oversight. Despite these corrective actions, TipRanks' AI Analyst, Spark, rates IBRX as Neutral due to weak financial fundamentals, though strong ANKTIVA commercialization offers a partial offset.
ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance
ImmunityBio (IBRX) has responded to the FDA Office of Prescription Drug Promotion (OPDP) regarding a TV ad and podcast, taking immediate corrective actions. The company removed the identified podcast from its corporate website and third-party hosts, confirmed the unbroadcast nature of the cited TV ad, and initiated a comprehensive review of its promotional materials to enhance compliance with new protocols and external regulatory counsel.
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns
ImmunityBio (NASDAQ: IBRX) has filed an 8-K detailing its comprehensive response to a Warning Letter from the FDA's Office of Prescription Drug Promotion concerning promotional communications for ANKTIVA®. The company removed the cited podcast from its website and confirmed the television advertisement was never broadcast, outlining immediate and planned corrective actions to enhance compliance. ImmunityBio reaffirmed its commitment to accurate and compliant advertising for ANKTIVA®, including executive training and external regulatory counsel.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged securities fraud. The lawsuit claims ImmunityBio made false and misleading statements about its Anktiva drug between January 19, 2026, and March 24, 2026. Investors who suffered losses during this period are encouraged to contact the firm to discuss their rights and participate in the lawsuit.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged securities fraud between January 19, 2026, and March 24, 2026. The lawsuit claims ImmunityBio made false and misleading statements about the capabilities of its Anktiva drug. Investors who suffered losses during this period are encouraged to contact the firm to participate in the lawsuit.
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
ImmunityBio, Inc. has responded to an FDA correspondence regarding a television advertisement and a podcast, outlining corrective actions and reaffirming its commitment to advertising compliance. The company stated the television ad was never aired and has removed the podcast from its platforms, while also implementing enhanced promotional review protocols, executive training, and external regulatory oversight. ImmunityBio also clarified the context of statements made by its founder in the podcast, which were intended to be aspirational regarding its drug development pipeline.
Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio
ImmunityBio has secured additional non-dilutive financing to support the growth of its immunotherapy platform and global expansion efforts. The company stated that this funding is aimed at improving patient outcomes. This update was shared by ImmunityBio on X.
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
ImmunityBio, Inc. (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter concerning misleading efficacy claims made by its executive chairman about its lead product, Anktiva. The FDA specifically cited claims that Anktiva could "treat all cancers" and "cure" cancer, which are not supported by data. This news led to a 21% drop in ImmunityBio's shares, erasing nearly $2 billion in market capitalization, prompting Hagens Berman to investigate potential federal securities law violations.
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc.
The Rosen Law Firm is reminding investors of ImmunityBio, Inc. (NASDAQ: IBRX) who purchased securities between January 19, 2026, and March 24, 2026, about the lead plaintiff deadline of May 26, 2026, in a securities class action lawsuit. The lawsuit alleges that ImmunityBio made false and misleading statements regarding Anktiva's capabilities and that investors suffered damages as a result. The firm encourages affected investors to secure counsel and potentially join the class action.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against ImmunityBio, Inc. (NASDAQ:IBRX) following a 21% stock drop on March 24, 2026. This decline occurred after Reuters reported that the FDA issued a warning letter to ImmunityBio, stating that one of the company's television advertisements and a podcast promoting its cancer therapy were false or misleading. The firm is encouraging investors who purchased ImmunityBio securities to learn more about the investigation and potentially assist with legal action.
Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against ImmunityBio, Inc. (IBRX) and its executives for alleged violations of the Securities Exchange Act of 1934. Investors who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, have until May 26, 2026, to seek appointment as lead plaintiff. The lawsuit claims that the company made false and misleading statements regarding the efficacy of its lead product, Anktiva, leading to significant financial and reputational consequences.
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio made false and misleading statements regarding its lead product, Anktiva, claiming it could make patients cancer-free and falsely marketing it as a cancer vaccine. This announcement follows a warning letter from the FDA, which caused ImmunityBio's stock price to fall by 21%.
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is alerting shareholders of ImmunityBio, Inc. (IBRX) about a securities fraud lawsuit, urging those who suffered losses to consider becoming lead plaintiffs by the May 26, 2026 deadline. The lawsuit alleges that ImmunityBio's Executive Chairman, Patrick Soon-Shiong, made misleading claims about the company's lead product, Anktiva, suggesting it "can cure and even prevent all cancer," which led to an FDA Warning Letter and a significant stock drop. The complaint asserts that the company made false and misleading statements about Anktiva’s capabilities, harming investors.
When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio
The FDA issued a warning letter to ImmunityBio over promotional claims for its bladder cancer therapy, Anktiva, made on a podcast and in a TV ad. The agency cited misleading statements about the drug's efficacy and lack of risk information, emphasizing that public remarks by pharma executives, regardless of the forum, can be considered regulated promotion. This action highlights the FDA's expanding scrutiny of pharmaceutical marketing beyond traditional advertising and reinforces the need for rigorous medical, legal, and regulatory review for all public communications to ensure fair balance and data-backed claims.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged securities fraud, encouraging investors who purchased shares between January 19, 2026, and March 24, 2026, to come forward. The lawsuit claims that ImmunityBio made false and misleading statements about the capabilities of its Anktiva drug, leading to investor damages when the truth was revealed. Investors have until May 26, 2026, to contact the firm to participate.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged securities fraud. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm by May 26, 2026. The lawsuit claims that ImmunityBio made false and misleading statements about the capabilities of its Anktiva drug, causing investors to suffer damages.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging ImmunityBio, Inc. (NASDAQ: IBRX) investors to join a class action lawsuit alleging securities fraud. The lawsuit claims that ImmunityBio made false and misleading statements about its Anktiva drug between January 19, 2026, and March 24, 2026. Investors who suffered losses during this period have until May 26, 2026, to contact the firm.
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit stems from a Bloomberg report on March 24, 2026, revealing that the FDA issued a Warning Letter to ImmunityBio due to allegedly inaccurate claims made by its Executive Chairman about the company's lead product, Anktiva. Following this news, ImmunityBio's stock price dropped over 21%, causing injury to investors.
ImmunityBio (IBRX) insider converts $25M note into 4.6M shares
ImmunityBio, Inc. reported that Nant Capital, LLC, an investment vehicle affiliated with Patrick Soon-Shiong, converted a $25 million convertible promissory note into 4,606,596 shares of common stock at a price of $5.427 per share on March 31, 2026. Following this transaction, Soon-Shiong's affiliated entities indirectly hold over 251 million shares of ImmunityBio, with an additional 29.7 million shares held directly, showcasing his significant influence over the company. The conversion was part of a previously established agreement allowing Nant Capital to convert the note into common stock between December 10, 2024, and December 31, 2027.
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein
Bernstein Liebhard LLP has issued a shareholder alert for ImmunityBio, Inc. (NASDAQ: IBRX) investors, reminding them of an upcoming deadline in a securities fraud class action lawsuit. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, and lost money, are encouraged to inquire about their legal rights. The lawsuit alleges that ImmunityBio made misrepresentations regarding its lead biologic product, ANKTIVA.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
The Rosen Law Firm has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio's CEO, Patrick Soon-Shiong, materially overstated Anktiva's capabilities, leading to false and misleading statements about the company's business and prospects. Investors who purchased IBRX securities during this period have until May 26, 2026, to move the Court to serve as lead plaintiff in the securities fraud lawsuit.
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter concerning misleading claims made by its executive chairman about the efficacy of its lead biologic product, Anktiva. The FDA stated that ImmunityBio's promotional materials falsely suggested Anktiva could treat all cancers and that patients would be cancer-free long-term, which is not supported by data. This news caused ImmunityBio's shares to drop over 21%, resulting in a loss of nearly $2 billion in market capitalization.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of ImmunityBio, Inc. (IBRX) who purchased securities between January 19, 2026, and March 24, 2026, to join a class action lawsuit. The lawsuit alleges that ImmunityBio made false and misleading statements about its Anktiva drug, causing investors to suffer damages. Affected shareholders have until May 26, 2026, to contact the firm.
Investors Seek Lead in ImmunityBio Class Action Lawsuit
Investors are seeking a lead plaintiff in a class action lawsuit against ImmunityBio, Inc. and its Executive Chairman, alleging the company misled investors about its experimental cancer treatment, Anktiva. The lawsuit claims false statements were made regarding Anktiva's capabilities and its classification as a cancer vaccine, leading to a significant stock price drop after an FDA warning letter. The final decision on the lead plaintiff is expected by May 26, 2026.
IBRX Stock Rises 8% As $100M Financing Boosts Balance Sheet
ImmunityBio (IBRX) saw its stock rise over 8% after securing $75 million in non-dilutive financing from Oberland Capital, increasing their total committed capital to $375 million. Additionally, Nant Capital converted $25 million of outstanding promissory notes into 4.6 million shares, reducing the company's debt. These financial moves aim to strengthen the balance sheet and support ImmunityBio's global expansion, particularly for its approved immunotherapy ANKTIVA.
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit — The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for ImmunityBio, Inc. (NASDAQ: IBRX), announcing a lead plaintiff deadline of May 26, 2026, for a securities class action lawsuit. The complaint alleges that during the period of January 19, 2026, to March 24, 2026, defendants made materially false and misleading statements regarding Anktiva's capabilities, leading to artificial inflation of the company's stock. Shareholders who purchased IBRX shares during this class period are encouraged to contact the firm to learn more about seeking lead plaintiff appointment.
Anktiva Gains Ground in Global Cancer Treatment Strategy
ImmunityBio Inc. (IBRX) shares have seen a significant increase following positive developments for its ANKTIVA plus BCG regimen, including its inclusion in the 2026 NCCN Bladder Cancer Guidelines and regulatory approval in Macau SAR, China. These advancements are expected to broaden its clinical use and market reach across 34 countries, contributing to the company's strong financial performance with high revenue growth. ImmunityBio is strategically expanding its presence in cancer treatment, positioning ANKTIVA as a key player in personalized medicine.
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
ImmunityBio, Inc. announced securing $75 million in non-dilutive financing from Oberland Capital, increasing their total committed capital to $375 million. This financing, along with the conversion of a $25 million promissory note held by Nant Capital into equity, strengthens ImmunityBio's balance sheet. The funds will support global expansion following recent approvals of ANKTIVA and advance its immunotherapy pipeline.
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) reminds investors of ImmunityBio, Inc. (NasdaqGS: IBRX) with substantial losses that they have until May 26, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit follows a 21% stock decline after the FDA issued a warning letter regarding ImmunityBio's cancer therapy advertisement, citing misrepresentation of its Anktiva product. KSF, a prominent securities litigation firm, alleges that ImmunityBio and its executives failed to disclose material information, violating federal securities laws.
ImmunityBio Hit with Class Action Lawsuit
ImmunityBio has been hit with a class action lawsuit by Bragar Eagel & Squire, P.C., alleging the company and its executives made false and misleading statements about the capabilities of its Anktiva product. The lawsuit covers the period between January 19, 2026, and March 24, 2026, and investors have until May 26, 2026, to apply as lead plaintiff. This legal challenge could have significant financial and reputational impacts on ImmunityBio.
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio made false and misleading statements regarding the capabilities of Anktiva, leading to investor damages. Investors have until May 26, 2026, to apply to be appointed as lead plaintiff.
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio materially overstated Anktiva's capabilities, leading to investors suffering damages when the truth emerged. Investors have until May 26, 2026, to apply to be appointed as lead plaintiff.
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
ImmunityBio, Inc. (IBRX) is facing a securities class action lawsuit following a strong FDA warning regarding misleading efficacy claims made by its executive chairman about their lead biologic product, Anktiva. The FDA specifically criticized statements suggesting Anktiva could treat "all cancers" and questioned its long-term effectiveness for bladder cancer, for which it is approved. This news caused ImmunityBio shares to drop over 21%, wiping out nearly $2 billion in market capitalization, and Hagens Berman is investigating potential federal securities law violations.
ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva
ImmunityBio (IBRX) is facing a securities lawsuit alleging that the company and its Executive Chairman, Dr. Patrick Soon-Shiong, made false and misleading statements about its cancer drug Anktiva. The lawsuit claims that public statements overstated Anktiva's capabilities and broader cancer-treatment potential beyond its FDA-approved use, leading to artificial inflation of the stock price. The stock dropped by approximately 21% after the FDA publicly released a warning letter on March 24, 2026, finding promotional materials for Anktiva to be false or misleading.
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, alleging federal securities law violations. The lawsuit claims that defendants made materially false and misleading statements about Anktiva's capabilities during the Class Period from January 19, 2026, to March 24, 2026. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of May 26, 2026.
IBRX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is reminding ImmunityBio (IBRX) investors of the May 26, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ImmunityBio and its executives, including Patrick Soon-Shiong, made misleading statements about "Anktiva's" capabilities, causing investor losses. The firm encourages affected investors who purchased securities between January 19, 2026, and March 24, 2026, to contact them to discuss their legal options.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of ImmunityBio, Inc. (NASDAQ: IBRX) to join a class action lawsuit alleging securities fraud. The lawsuit claims that ImmunityBio made false and misleading statements about its Anktiva drug, causing investors to suffer losses. Investors who purchased securities between January 19, 2026, and March 24, 2026, have until May 26, 2026, to contact the firm.
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out – Hagens Berman
ImmunityBio (IBRX) is facing a securities class action lawsuit filed by Hagens Berman after the FDA issued a warning letter concerning misleading efficacy claims made by the company's executive chairman about its lead biologic product, Anktiva. The FDA's letter stated that ImmunityBio's promotional materials falsely suggested Anktiva could treat "all cancers" and cure NMIBC patients long-term, despite the drug only being approved for a specific type of bladder cancer. This news led to a 21% drop in ImmunityBio's stock price, wiping out nearly $2 billion in market capitalization.
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced an investor alert for purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities, noting an opportunity to lead a class action lawsuit. The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements about Anktiva, the company's leading biological product, including claims that it could cure or prevent all cancer. The action stems from a U.S. Food and Drug Administration warning letter citing misbranded communications about Anktiva, which led to a 21% drop in ImmunityBio's stock price.
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2025. The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements about Anktiva's capabilities and its designation as a cancer vaccine. The firm is seeking lead plaintiffs for the lawsuit, which follows a warning letter from the FDA regarding misbranding of Anktiva.
Biotech Company Achieves Key Bladder Cancer Milestone in California
ImmunityBio Inc. announced a significant milestone in its trial for Anktiva, combined with BCG, for bladder cancer treatment. An Independent Data Monitoring Committee confirmed the study's statistical power, meaning no further enrollment is needed, and the company remains on track for a supplemental Biologics License Application filing in Q4 2026. This positive update arrives amidst a fluctuating biotech market and recent FDA criticisms regarding the company's prior marketing of Anktiva.
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP has issued a deadline alert for ImmunityBio (NASDAQ: IBRX) investors, reminding them of the May 26, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ImmunityBio and its executives made false or misleading statements regarding Anktiva's capabilities and that investors suffered losses when the true details emerged, particularly after the company disclosed that median overall survival had not yet been reached in a Phase 2 clinical trial for glioblastoma treatment. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the law firm to discuss their options.
IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors
Kirby McInerney LLP has filed a securities class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio's Executive Chairman, Patrick Soon-Shiong, overstated the capabilities of Anktiva, an FDA-approved immunotherapy. This follows a warning letter from the FDA regarding "false or misleading" promotional material for Anktiva, which caused ImmunityBio's stock to drop by over 21%.
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is reminding investors of ImmunityBio (IBRX) about the May 26, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements regarding Anktiva's capabilities, leading to investor damages when the truth emerged. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm to discuss their legal options.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
The Rosen Law Firm has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio's defendant Patrick Soon-Shiong overstated Anktiva's capabilities, leading to false and misleading statements about the company's business. Investors who wish to serve as lead plaintiff must move the Court by May 26, 2026.
ImmunityBio, Soon-Shiong Sued by Investor Over FDA Admonition
ImmunityBio Inc. and its executive chairman Patrick Soon-Shiong are facing a proposed class action lawsuit from an investor. The lawsuit alleges they overhyped their bladder cancer drug, Anktiva, on Sean Spicer’s podcast. This legal action follows a warning letter from the FDA regarding Soon-Shiong’s claims that the drug could treat “all cancers.”
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
ImmunityBio announced that its QUILT-2.005 randomized clinical trial, evaluating ANKTIVA® plus BCG for BCG-naïve non-muscle invasive bladder cancer, is adequately powered to detect clinically meaningful differences. The Independent Data Monitoring Committee confirmed that no additional enrollment is required for the study, which has completed enrollment with 366 patients. ImmunityBio anticipates submitting a supplemental Biologics License Application (BLA) in 2026 based on the final data analysis.
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and its Executive Chairman. The lawsuit alleges that ImmunityBio made false and misleading statements regarding its lead product, Anktiva, and its capabilities, leading to substantial losses for investors. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2025, are encouraged to come forward to potentially lead the lawsuit.
Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating ImmunityBio, Inc. (IBRX) for potential securities law violations after the FDA issued a warning letter on March 24, 2026. The FDA stated that ImmunityBio's TV ad and podcast misrepresented the efficacy and administration of its drug Anktiva, leading to a 21% drop in the company's stock price. Kaplan Fox is encouraging affected investors to contact them for more information.
